SEC Comment Letter 0000000000-24-009247 to Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc.
Date: Aug. 13, 2024 · CIK: 0001867096 · Accession: 0000000000-24-009247
AI Filing Summary & Sentiment
File numbers found in text: 001-40880
Letter
August 13, 2024 Steven Pieper Chief Financial Officer Xeris Biopharma Holdings, Inc. 1375 West Fulton Street, Suite 100 Chicago, IL 60607 Re:Xeris Biopharma Holdings, Inc. Form 10-K for the year ended December 31, 2023 Form 10-Q for the quarterly period ended March 31, 2024 File No. 001-40880 Dear Steven Pieper: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
August 13, 2024
Steven Pieper
Chief Financial Officer
Xeris Biopharma Holdings, Inc.
1375 West Fulton Street, Suite 100
Chicago, IL 60607
Re:Xeris Biopharma Holdings, Inc.
Form 10-K for the year ended December 31, 2023
Form 10-Q for the quarterly period ended March 31, 2024
File No. 001-40880
Dear Steven Pieper:
We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences